The late-phase human clinical trials of the Oxford-AstraZeneca vaccine, Covishield, are working smoothly at the PGI and those administered the dose have not shown any side effects so far.
An official statement published by the institute today reads, “The second phase of human clinical trials of Covishield, a potential vaccine developed by Oxford University, is going well at the PGI. Till date, 97 volunteers have been screened. Of them, 65 have already been vaccinated since September 25 when the PGI started administering the first dose of the vaccine to the volunteers. Among the 65 volunteers given the first dose, 53 have already completed seven days post-vaccination without any major side effects.”